Home
About
Overview
Sharing Data
ORCID
Help
History (5)
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Molecular abnormalities in lung cancer.
Molecular alterations in lung cancer. Impact on prognosis.
Phase I Dose-Escalation and -Expansion Study of Telisotuzumab (ABT-700), an Anti-c-Met Antibody, in Patients with Advanced Solid Tumors.
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Molecular abnormalities in lung cancer.
Molecular abnormalities in lung cancer. J Clin Oncol. 1998 Mar; 16(3):1207-17.
View in:
PubMed
subject areas
Animals
Apoptosis
Carcinoma, Non-Small-Cell Lung
Carcinoma, Small Cell
Cell Cycle
Chromosome Aberrations
Cytogenetics
Gene Expression
Genes, Tumor Suppressor
Humans
Lung Neoplasms
Mutation
Oncogenes
Signal Transduction
authors with profiles
Ravi Salgia